

John W. Eikelboom

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/9156826/publications.pdf](https://exaly.com/author-pdf/9156826/publications.pdf)

Version: 2025-02-01

582

PR articles

63,614

PR citations

1249

104

PR h-index

748

246

g-index

720

documents

74289

doc citations

1305

112

h-index

58765

citing authors

#	ARTICLE	IF	CITATIONS
1	Anticoagulation for Patients with Atrial Fibrillation Receiving Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2025, 36, 901-910.	0.4	8
2	Neuroglial Biomarkers for Risk Assessment of Ischemic Stroke and Other Cardiovascular Events in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. <i>Journal of the American Heart Association</i> , 2025, 14, .	4.0	2
3	Choosing the optimal oral anticoagulant for stroke prevention in atrial fibrillation: direct oral anticoagulants vs vitamin K antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2025, 23, 1207-1214.	3.8	0
4	Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease. <i>Stroke</i> , 2025, 56, 380-389.	6.0	6
5	Sex Differences in Permanent Discontinuation of Trial Medication in Chronic Coronary Artery Disease: The LoDoCo2 Trial. <i>Journal of the American Heart Association</i> , 2025, 14, .	4.0	3
6	Association of Biomarkers With Intracerebral Hematoma Expansion and Arterial Thromboembolic Events in Patients With Acute Intracranial Hemorrhage: The ANNEXA-I Biomarker Substudy. <i>Stroke</i> , 2025, 56, 1807-1815.	6.0	0
7	Single Bolus r-PA Before Primary PCI for ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2024, 17, .	4.8	6
8	Efficacy and Safety of Nonâ€Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation. <i>Circulation</i> , 2024, 149, 932-943.	18.1	21
9	Optimizing warfarin dosing for patients with atrial fibrillation using machine learning. <i>Scientific Reports</i> , 2024, 14, .	3.4	16
10	Anticoagulation for mechanical aortic valves: An international survey of current practice patterns and perceptions. <i>Thrombosis Update</i> , 2024, 14, 100164.	0.6	2
11	Urinary thromboxane and risk of cardiovascular events: role of aspirin. <i>European Heart Journal</i> , 2024, 45, 1368-1370.	2.2	1
12	Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. <i>Nature Reviews Cardiology</i> , 2024, 21, 574-592.	35.7	12
13	A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. <i>Kidney International</i> , 2024, 106, 145-153.	5.3	24
14	The Effects of Pantoprazole on Kidney Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2024, 35, 901-909.	0.4	9
15	The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis. <i>Circulation</i> , 2024, 149, 1315-1318.	18.1	4
16	Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, lowâ€dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 60, 737-748.	3.7	5
17	Results of the COMPASS Trial Analyzed Using Win Ratio Compared With Conventional Analytic Approaches. <i>Canadian Journal of Cardiology</i> , 2024, 40, 2171-2179.	2.6	3
18	Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation. <i>Circulation</i> , 2024, 150, 1090-1100.	18.1	9

#	ARTICLE	IF	CITATIONS
19	Authors' Reply: Proton Pump Inhibitors May Cause a Decline in eGFR by Inhibiting Organic Cation Transporter 2â€“Dependent Creatinine Secretion. <i>Journal of the American Society of Nephrology: JASN</i> , 2024, 35, 1614-1614.	0.4	0
20	Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patientâ€“Level Metaâ€“Analysis From COMBINE AF. <i>Journal of the American Heart Association</i> , 2024, 13, .	4.0	13
21	Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Lowâ€“Dose Rivaroxaban or the Combination: Secondary Analysis of the <scp>COMPASS</scp> Randomised Controlled Trial. Authors' Reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2024, 60, 1652-1653.	3.7	0
22	Rivaroxaban plus aspirin after lowerâ€“extremity revascularization. <i>Expert Review of Hematology</i> , 2024, 17, 877-884.	2.0	0
23	Conduit selection and early graft failure in coronary artery bypass surgery: A post hoc analysis of the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) coronary artery bypass grafting study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 1080-1089.e1.	2.6	22
24	Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2023, 9, 208-219.	4.0	6
25	Factor XI inhibitors: cardiovascular perspectives. <i>European Heart Journal</i> , 2023, 44, 280-292.	2.2	58
26	Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. <i>European Heart Journal</i> , 2023, 44, 208-218.	2.2	47
27	Validating fatty acid binding protein 3 as a diagnostic andâ€“prognostic biomarker for peripheral arterial disease: aâ€“three-year prospective follow-up study. <i>EClinicalMedicine</i> , 2023, 55, 101766.	8.2	15
28	Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors. <i>Circulation</i> , 2023, 147, 1026-1038.	18.1	124
29	Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. <i>European Heart Journal</i> , 2023, 44, 1807-1814.	2.2	46
30	Hypotension-Avoidance Versus Hypertension-Avoidance Strategies in Noncardiac Surgery. <i>Annals of Internal Medicine</i> , 2023, 176, 605-614.	9.7	130
31	Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CAREâ€“COALITION VIII randomised clinical trial. <i>EClinicalMedicine</i> , 2023, 60, 102004.	8.2	15
32	Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2023, 30, 1950-1962.	2.0	13
33	Plasma angiotensin-converting enzyme-2 and its association with heart failure in patients with atrial fibrillation. <i>Europace</i> , 2023, 25, .	2.0	9
34	Adult malaria mortality during 2019 at Bo Government Hospital, Sierra Leone. <i>Gates Open Research</i> , 2023, 7, 48.	0.7	0
35	Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease. <i>Seminars in Nephrology</i> , 2023, 43, 151484.	2.3	4
36	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. <i>Cardiovascular Research</i> , 2022, 118, 295-304.	5.5	15

#	ARTICLE	IF	CITATIONS
37	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. <i>Cardiovascular Research</i> , 2022, 118, 897-903.	5.5	34
38	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 462-473.	4.0	13
39	Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 648-659.	4.0	22
40	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2112-2123.	5.5	40
41	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	2.0	33
42	Aortic plaque burden predicts vascular events in patients with cardiovascular disease: The EAST-NOGA study. <i>Journal of Cardiology</i> , 2022, 79, 144-152.	2.1	22
43	Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on-treatment platelet reactivity: the OPTimal Management of Antithrombotic Agents (OPTIMA) Trial. <i>British Journal of Haematology</i> , 2022, 196, 424-432.	2.7	6
44	Prolonged Blood Storage and Risk of Posttransfusion Acute Kidney Injury. <i>Anesthesiology</i> , 2022, 136, 138-147.	2.2	4
45	Advances in anticoagulation: patients with bioprosthetic heart valves. <i>Cardiovascular Research</i> , 2022, 118, e26-e28.	5.5	5
46	Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial. <i>Canadian Journal of Kidney Health and Disease</i> , 2022, 9, .	1.2	5
47	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	18.1	322
48	Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, .	1.7	4
49	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. <i>Thrombosis and Haemostasis</i> , 2022, 122, 998-1005.	4.1	32
50	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study. <i>TH Open</i> , 2022, 06, e10-e17.	1.4	6
51	Inflammation as a Mechanism and Therapeutic Target in Peripheral Artery Disease. <i>Canadian Journal of Cardiology</i> , 2022, 38, 588-600.	2.6	16
52	Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis. <i>European Stroke Journal</i> , 2022, 7, 92-98.	3.8	22
53	Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12650.	0.5	19
54	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. <i>Circulation</i> , 2022, 145, 626-628.	18.1	26

#	ARTICLE	IF	CITATIONS
55	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. <i>CJC Open</i> , 2022, 4, 568-576.	1.6	7
56	Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol. <i>BMJ Open</i> , 2022, 12, e060000.	1.9	32
57	Tranexamic Acid in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2022, 386, 1986-1997.	34.6	257
58	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	4.0	17
59	Dual antithrombotic treatment in chronic coronary syndrome: European Society of Cardiology criteria vs. CHADS-P2A2RC score. <i>European Heart Journal</i> , 2022, 43, 996-1004.	2.2	15
60	Venous and arterial thrombosis in COVID-19: An updated narrative review. <i>Journal of Infection and Public Health</i> , 2022, 15, 689-702.	3.7	9
61	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.	11.2	44
62	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. <i>Circulation</i> , 2022, 145, 1875-1877.	18.1	7
63	Efficacy and Safety of Intensified Versus Standard Prophylactic Anticoagulation Therapy in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.8	5
64	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. <i>European Heart Journal</i> , 2022, 43, 3542-3552.	2.2	15
65	Impact of Insulin Receptor Substrate rs956115 and CYP2C19 rs4244285 Genotypes on Clinical Outcome of Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2022, 11, .	4.0	2
66	Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. <i>European Heart Journal</i> , 2022, 43, 3512-3527.	2.2	34
67	A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction. <i>Circulation</i> , 2022, 146, 1196-1206.	18.1	135
68	GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. <i>Clinical Research in Cardiology</i> , 2022, 112, 759-771.	2.8	7
69	Factor XI inhibitors: what should clinicians know. <i>Current Opinion in Cardiology</i> , 2022, 38, 88-93.	1.6	4
70	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2021, . . .	11.2	56
71	Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. <i>Cardiovascular Research</i> , 2021, 117, 2030-2044.	5.5	47
72	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , 2021, 117, 576-584.	5.5	48

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021, 117, 942-949.	5.5	20
74	Mortality Benefit in the Compass Trial: is It Related to Superior Statistical Power Or Better Efficacy and safety?. <i>Future Cardiology</i> , 2021, 17, 175-182.	1.0	1
75	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , 2021, 126, 163-171.	4.9	56
76	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , 2021, 126, 172-180.	4.9	12
77	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. <i>Thrombosis and Haemostasis</i> , 2021, 121, 518-528.	4.1	8
78	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021, 77, 511-525.	2.3	13
79	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	2.9	25
80	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. <i>TH Open</i> , 2021, 05, e84-e88.	1.4	3
81	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2021, 143, 583-596.	18.1	209
82	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1097-1106.	4.1	25
83	Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e71-e71.	4.0	2
84	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal</i> , 2021, 42, 2765-2775.	2.2	216
85	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.	2.3	161
86	Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. <i>Circulation</i> , 2021, 143, 1863-1873.	18.1	43
87	Urinary fatty acid binding protein 3 (uFABP3) is a potential biomarker for peripheral arterial disease. <i>Scientific Reports</i> , 2021, 11, .	3.4	23
88	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.	4.0	8
89	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021, 52, 2096-2105.	6.0	55
90	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2021, 149, 27-35.	1.8	20

#	ARTICLE	IF	CITATIONS
91	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 14-23.	2.3	49
92	Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease. <i>PLoS ONE</i> , 2021, 16, e0253792.	2.3	4
93	Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1815-1823.	2.0	13
94	Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?. <i>European Heart Journal</i> , 2021, 42, 3143-3145.	2.2	12
95	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <i>Atherosclerosis</i> , 2021, 331, 38-44.	1.5	9
96	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2726-2737.	3.8	26
97	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 337, 9-15.	2.2	7
98	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2021, 78, 859-866.	2.3	47
99	Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 1091-1102.	2.7	2
100	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. <i>JAMA Cardiology</i> , 2021, 6, 1042.	11.2	62
101	Direct oral anticoagulant dose selection: Challenging cases. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2680-2686.	3.8	6
102	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. <i>Kidney International</i> , 2021, 100, 1199-1207.	5.3	40
103	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. <i>Europace</i> , 2021, 23, 748-756.	2.0	10
104	Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 53, 697-707.	1.9	0
105	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. <i>JAMA Neurology</i> , 2020, 77, 43.	17.6	67
106	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	2.0	29
107	Selection Bias, Orthopaedic Style. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 631-633.	3.3	13
108	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 4037-4046.	2.2	107

#	ARTICLE	IF	CITATIONS
109	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2020, 76, 594-622.	2.3	316
110	Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?â€”A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1323-1329.	4.1	31
111	Direct oral anticoagulants: evidence and unresolved issues. <i>Lancet, The</i> , 2020, 396, 1767-1776.	62.3	159
112	Is aspirin safer than a direct oral anticoagulant for patients with atrial fibrillation at high risk of bleeding?. <i>European Journal of Internal Medicine</i> , 2020, 79, 25-26.	2.7	1
113	Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease. <i>Future Cardiology</i> , 2020, 16, 597-611.	1.0	1
114	Tranexamic acid and rosuvastatin in patients at risk of cardiovascular events after noncardiac surgery: a pilot of the POISE-3 randomized controlled trial. <i>Pilot and Feasibility Studies</i> , 2020, 6, .	1.5	4
115	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	6.0	24
116	Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1838-1847.	34.6	1,804
117	Evaluation of the Age, Biomarkers, and Clinical Historyâ€”Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	6.6	8
118	Trial Design Principles for Patients at Highâ€”Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	2.3	53
119	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, .	4.0	55
120	Fatty acid binding protein 3 is associated with peripheral arterial disease. <i>JVS Vascular Science</i> , 2020, 1, 168-175.	0.7	33
121	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020, 41, 2848-2859.	2.2	30
122	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	4.1	232
123	The COMPASS Trial. <i>Circulation</i> , 2020, 142, 40-48.	18.1	141
124	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	18.1	51
125	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	18.1	137
126	Oral factor Xa inhibitors and risk of subdural hematoma. <i>Neurology</i> , 2020, 95, .	1.0	1

#	ARTICLE	IF	CITATIONS
127	Plasma Levels of Protein Z in Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 815-822.	4.1	9
128	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	35.7	115
129	Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Thrombosis and Haemostasis</i> , 2020, 120, 484-494.	4.1	30
130	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.	2.3	2,612
131	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.	2.5	24
132	Combination Antithrombotic Treatment for prevention of recurrent Ischemic Stroke in IntraCranial Atherosclerotic Disease: CATIS-ICAD (2639). <i>Neurology</i> , 2020, 94, .	1.0	1
133	The Ross procedure versus prosthetic and homograft aortic valve replacement: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 247-255.	1.4	28
134	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	6.4	14
135	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	0.9	424
136	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3271-3280.	2.3	118
137	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	0.9	138
138	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	0.5	11
139	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2019, 218, 46-56.	2.9	93
140	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. <i>Stroke</i> , 2019, 50, 3347-3354.	6.0	45
141	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , 2019, 70, 1-7.	2.7	25
142	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, .	6.1	31
143	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019, 40, 3771-3778a.	2.2	36
144	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	18.1	45

#	ARTICLE	IF	CITATIONS
145	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	2.3	39
146	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1760-1768.	2.3	32
147	Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 668-674.	4.1	27
148	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	4.1	9
149	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	18.1	138
150	Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2769-2772.	2.3	7
151	Pulmonary embolism: update on diagnosis and management. <i>Medical Journal of Australia</i> , 2019, 211, 82-87.	1.7	30
152	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 529-537.	18.1	93
153	Deep vein thrombosis: update on diagnosis and management. <i>Medical Journal of Australia</i> , 2019, 210, 516-524.	1.7	147
154	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	2.2	491
155	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	18.1	635
156	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2243-2250.	2.3	44
157	Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 2846-2856.	18.1	14
158	External applicability of the COMPASS trial: the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 192-199.	4.0	14
159	How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. <i>Blood</i> , 2019, 133, 2269-2278.	4.2	19
160	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, .	4.0	53
161	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	34.6	872
162	Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion. <i>Transfusion</i> , 2019, 59, 1850-1856.	0.8	14

#	ARTICLE	IF	CITATIONS
163	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 720-728.	34.6	645
164	Review: After PCI with DESs, long- and standard-term DAPT increase some adverse outcomes vs short-term DAPT. <i>Annals of Internal Medicine</i> , 2019, 171, JC54.	9.7	0
165	Andexanet Alfa for Reversal of Factor Xa Inhibitors: A Critical Review of the Evidence. <i>Future Cardiology</i> , 2019, 15, 395-404.	1.0	7
166	Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2019, 218, 100-109.	2.9	8
167	How Did We Get Here?: A Historical Review and Critical Analysis of Anticoagulation Therapy Following Mechanical Valve Replacement. <i>Circulation</i> , 2019, 140, 1933-1942.	18.1	25
168	The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. <i>International Journal of Cardiology</i> , 2019, 278, 7-13.	2.2	21
169	The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. <i>Transfusion</i> , 2019, 59, 482-491.	0.8	60
170	Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1-11.	3.1	58
171	Stroke prevention in AF: Of Asians and non-Asians. <i>European Heart Journal</i> , 2019, 40, 1528-1530.	2.2	4
172	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the Atrial Fibrillation Registry Trial. <i>Journal of the American Heart Association</i> , 2019, 8, .	4.0	22
173	Antiplatelet Therapy versus Anticoagulation after Surgical Bioprosthetic Aortic Valve Replacement: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 328-339.	4.1	9
174	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. <i>Journal of the American College of Cardiology</i> , 2019, 73, 121-130.	2.3	87
175	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 153-158.	1.8	10
176	International Normalized Ratio Targets for Left-Sided Mechanical Valve Replacement. <i>Thrombosis and Haemostasis</i> , 2018, 118, 906-913.	4.1	16
177	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	2.2	37
178	Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). <i>Canadian Journal of Cardiology</i> , 2018, 34, 295-302.	2.6	26
179	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, Tj ETQq1 1 0.784314, rrgBT /Overlock 10 T	2.2	111
180	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. <i>British Journal of Anaesthesia</i> , 2018, 120, 645-656.	4.9	119

#	ARTICLE	IF	CITATIONS
181	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. <i>American Heart Journal</i> , 2018, 198, 169-177.	2.9	15
182	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018, 39, 750-757a.	2.2	79
183	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2306-2315.	2.3	409
184	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <i>American Heart Journal</i> , 2018, 199, 59-67.	2.9	38
185	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.	62.3	476
186	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	62.3	782
187	Low-dose Rivaroxaban Plus Aspirin for the Prevention of Cardiovascular Events: an Evaluation of COMPASS. <i>Future Cardiology</i> , 2018, 14, 443-453.	1.0	6
188	In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1895-1901.	4.1	9
189	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.6	18
190	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	18.1	221
191	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018, 39, 3973-3979.	2.2	167
192	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	2.3	71
193	Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 2325-2334.	62.3	289
194	Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. <i>European Journal of Haematology</i> , 2018, 101, 362-367.	1.8	6
195	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	2.3	98
196	Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 310-315.	1.9	3
197	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2017, , ehv643.	2.2	70
198	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, , ehw069.	2.2	107

#	ARTICLE	IF	CITATIONS
199	Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. <i>Vox Sanguinis</i> , 2017, 112, 268-278.	1.1	52
200	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	4.0	85
201	Clinical Implications of Reversal Agents for Direct Oral Anticoagulants. <i>Future Cardiology</i> , 2017, 13, 153-159.	1.0	7
202	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	2.9	49
203	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	2.6	148
204	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 566.	11.2	128
205	Short-Term versus Long-Term Blood Storage. <i>New England Journal of Medicine</i> , 2017, 376, 1091-1094.	34.6	5
206	A Test in Context: D-Dimer. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2411-2420.	2.3	500
207	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. <i>Lancet Haematology</i> , 2017, 4, e544-e552.	9.6	38
208	Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. <i>CMAJ Open</i> , 2017, 5, E594-E603.	1.5	7
209	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	34.6	2,157
210	Aortic valve replacement in younger patients. <i>European Heart Journal</i> , 2017, 38, 3378-3381.	2.2	7
211	Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. <i>Thrombosis Research</i> , 2017, 157, 165-166.	2.3	9
212	In Reply. <i>Anesthesiology</i> , 2017, 127, 401-402.	2.2	0
213	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3042-3067.	2.3	312
214	Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017, 377, 431-441.	34.6	1,082
215	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	4.1	57
216	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017, 01, e139-e145.	1.4	41

#	ARTICLE	IF	CITATIONS
217	Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. <i>TH Open</i> , 2017, 01, e82-e91.	1.4	16
218	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 257-270.	4.1	11
219	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	4.1	36
220	D-dimer and factor VIIa in atrial fibrillation – prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016, 115, 921-930.	4.1	37
221	Laboratory measurement of the direct oral anticoagulants. <i>British Journal of Haematology</i> , 2016, 172, 315-336.	2.7	92
222	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016, 220, 417-428.	2.2	10
223	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 2094-2098.	18.1	19
224	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet</i> , The, 2016, 387, 2302-2311.	62.3	447
225	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016, 20, .	6.0	43
226	Evolving Treatments for Arterial and Venous Thrombosis. <i>Circulation Research</i> , 2016, 118, 1409-1424.	18.2	110
227	Trends in incidence and prevalence of hospitalization for atrial fibrillation and associated mortality in Western Australia, 1995–2010. <i>International Journal of Cardiology</i> , 2016, 208, 19-25.	2.2	43
228	Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2016, 129, e35-e36.	2.0	30
229	Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. <i>American Heart Journal</i> , 2016, 178, 145-150.	2.9	63
230	Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. <i>Blood</i> , 2016, 127, 400-410.	4.2	107
231	Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. <i>American Journal of Medicine</i> , 2016, 129, e247-e248.	2.0	16
232	Bleeding with direct oral anticoagulants vs warfarin: clinical experience. <i>American Journal of Emergency Medicine</i> , 2016, 34, 3-8.	1.6	29
233	Genetic Determinants of Warfarin Maintenance Dose and Time in Therapeutic Treatment Range: A RE-LY Genomics Substudy. <i>Pharmacogenomics</i> , 2016, 17, 1425-1439.	1.5	23
234	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	18.1	89

#	ARTICLE	IF	CITATIONS
235	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	34.6	752
236	Response by Weitz and Eikelboom to Letter Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants". <i>Circulation</i> , 2016, 134, .	18.1	0
237	Urgent Need to Measure Effects of Direct Oral Anticoagulants. <i>Circulation</i> , 2016, 134, 186-188.	18.1	56
238	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. <i>New England Journal of Medicine</i> , 2016, 375, 1937-1945.	34.6	316
239	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	4.8	89
240	Perioperative Aspirin for Prevention of Venous Thromboembolism. <i>Anesthesiology</i> , 2016, 125, 1121-1129.	2.2	25
241	Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study. <i>European Journal of Internal Medicine</i> , 2016, 33, 55-59.	2.7	27
242	Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1108-1116.	2.6	6
243	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016, 102, 57-62.	4.0	34
244	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1300-1308.	2.3	185
245	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	2.3	42
246	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1332-1339.	2.6	7
247	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. <i>Transfusion Medicine Reviews</i> , 2016, 30, 25-29.	1.6	16
248	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016, 140, 81-88.	2.3	15
249	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. <i>Lancet Haematology</i> , 2016, 3, e246-e254.	9.6	63
250	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	2.0	19
251	Association of cardiac biomarkers with acute kidney injury after cardiac surgery: A multicenter cohort study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 245-251.e4.	2.6	38
252	Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. <i>American Heart Journal</i> , 2016, 173, 102-107.	2.9	36

#	ARTICLE	IF	CITATIONS
253	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , 2016, 45, 77-83.	1.8	106
254	Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 43, 291-301.	1.9	39
255	Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2015, 15, .	2.0	125
256	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 625-632.	4.1	217
257	Exploratory studies on the age of transfused blood and in-hospital mortality in patients with cardiovascular diagnoses. <i>Transfusion</i> , 2015, 55, 364-372.	0.8	25
258	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1049-1057.	4.1	27
259	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2015, 114, 933-944.	4.1	11
260	Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. <i>Vascular Health and Risk Management</i> , 2015, , 343.	4.1	69
261	Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 114, 768-777.	4.1	37
262	Timing the First Postoperative Dose of Anticoagulants. <i>Chest</i> , 2015, 148, 587-595.	1.0	16
263	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015, 114, 198-205.	4.1	133
264	Changes in Renal Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2481-2493.	2.3	215
265	Idarucizumab. <i>Circulation</i> , 2015, 132, 2412-2422.	18.1	150
266	Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials. <i>Thrombosis Research</i> , 2015, 136, 1087-1098.	2.3	19
267	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>European Heart Journal</i> , 2015, 36, 281-288.	2.2	291
268	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2015, 132, 796-803.	18.1	110
269	Perioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgery. <i>Kidney International</i> , 2015, 88, 576-583.	5.3	28
270	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015, 373, 511-520.	34.6	1,488

#	ARTICLE	IF	CITATIONS
271	Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 618-627.	3.8	79
272	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. <i>European Heart Journal</i> , 2015, 36, 1454-1462.	2.2	118
273	Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. <i>Pediatric Nephrology</i> , 2015, 30, 1519-1527.	1.7	68
274	Cardiac Biomarkers and Acute Kidney Injury After Cardiac Surgery. <i>Pediatrics</i> , 2015, 135, e945-e956.	4.5	57
275	Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3123-3132.	0.4	193
276	Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 42, 90-98.	1.9	9
277	Management of bleeding with oral anticoagulants in patients with atrial fibrillation. <i>Hamostaseologie</i> , 2015, 35, 351-357.	1.4	1
278	Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. <i>Thrombosis and Haemostasis</i> , 2014, 112, 918-923.	4.1	62
279	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. <i>Thrombosis and Haemostasis</i> , 2014, 111, 10-13.	4.1	11
280	Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1120-1128.	4.1	19
281	Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Trial." <i>Circulation</i> , 2014, 130, 1081-1082.	18.1	0
282	Betrixaban (PRT054021): pharmacology, Dose Selection and Clinical Studies. <i>Future Cardiology</i> , 2014, 10, 43-52.	1.0	34
283	Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin." <i>Circulation</i> , 2014, 130, .	18.1	0
284	Response to Letter Regarding Article, "Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study." <i>Circulation</i> , 2014, 130, .	18.1	4
285	Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2014, 29, 1-9.	1.6	7
286	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , 2014, 35, 1856-1863.	2.2	30
287	Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far?. <i>European Heart Journal</i> , 2014, 35, 1831-1833.	2.2	14
288	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. <i>Thrombosis and Haemostasis</i> , 2014, 112, 798-807.	4.1	50

#	ARTICLE	IF	CITATIONS
289	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 321-328.	2.3	792
290	Efficacy and Safety of Warfarin VS. Antiplatelet Therapy in Patients with Systolic Heart Failure and Sinus Rhythm: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>International Journal of Stroke</i> , 2014, 9, 199-206.	6.4	14
291	Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. <i>American Heart Journal</i> , 2014, 168, 239-247.e1.	2.9	54
292	A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. <i>European Journal of Epidemiology</i> , 2014, 29, 181-190.	5.3	107
293	Aspirin in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2014, 370, 1494-1503.	34.6	836
294	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 961-970.	18.1	376
295	Clonidine in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2014, 370, 1504-1513.	34.6	338
296	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 2242-2248.	2.2	47
297	Novel Oral Anticoagulants: A Focused Review for Stroke Physicians. <i>International Journal of Stroke</i> , 2014, 9, 71-78.	6.4	12
298	Colchicine for Secondary Prevention of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2014, 16, .	4.7	34
299	Targeting Cholesterol Crystal-Induced Inflammation for the Secondary Prevention of Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014, 19, 45-52.	2.5	43
300	Antithrombotic Therapy After Acute Ischemic Stroke in Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 3637-3642.	6.0	22
301	Aspirin for the Prevention of Recurrent Venous Thromboembolism. <i>Circulation</i> , 2014, 130, 1062-1071.	18.1	262
302	Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. <i>BMJ Open</i> , 2014, 4, e005674.	1.9	6
303	Myocardial Injury after Noncardiac Surgery. <i>Anesthesiology</i> , 2014, 120, 564-578.	2.2	877
304	Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS. <i>Annals of Internal Medicine</i> , 2014, 160, JC4.	9.7	0
305	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 40, 231-239.	1.9	36
306	Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 39, 23-34.	1.9	28

#	ARTICLE	IF	CITATIONS
307	Bleeding in Patients with Atrial Fibrillation Treated with Non Vitamin K Antagonist Oral Anticoagulants: A Population-Based Study. <i>Blood</i> , 2014, 124, 343-343.	4.2	2
308	Utilization of Universal Group O Blood By Non Group O Recipients. <i>Blood</i> , 2014, 124, 5103-5103.	4.2	1
309	Systematic Review of Observational Studies Assessing Bleeding Risk in Patients with Atrial Fibrillation Not Using Anticoagulants. <i>PLoS ONE</i> , 2014, 9, e88131.	2.3	16
310	New oral anticoagulants in elderly patients. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 215-224.	1.7	62
311	Novel Oral Anticoagulants for Atrial Fibrillation. <i>Current Atherosclerosis Reports</i> , 2013, 15, .	4.7	15
312	Targeting the Unstable Plaque in Acute Coronary Syndromes. <i>Clinical Therapeutics</i> , 2013, 35, 1099-1107.	2.7	20
313	Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. <i>New England Journal of Medicine</i> , 2013, 369, 1206-1214.	34.6	1,370
314	Adherence to anticoagulant treatment with dabigatran in a real-world setting. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1295-1299.	3.8	91
315	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	18.1	262
316	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013, 128, 237-243.	18.1	199
317	The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial. <i>BMC Geriatrics</i> , 2013, 13, .	3.3	41
318	Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. <i>Cardiology and Therapy</i> , 2013, 2, 135-149.	2.3	44
319	Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. <i>Circulation</i> , 2013, 127, 1404-1412.	18.1	245
320	Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. <i>Circulation</i> , 2013, 127, 634-640.	18.1	462
321	Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 404-410.	2.3	957
322	Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS ₂ and CHA ₂ DS ₂	6.1	26
323	Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion. <i>Thrombosis Research</i> , 2013, 131, 300-303.	2.3	3
324	Pacemaker-Detected Atrial Fibrillation in Patients With Pacemakers: Prevalence, Predictors, and Current Use of Oral Anticoagulation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 224-228.	2.6	86

#	ARTICLE	IF	CITATIONS
325	Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 900-908.	2.3	66
326	Anti- ϵ PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 253-260.	3.8	14
327	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013, 34, 170-176.	2.2	171
328	Aspirin for Preventing Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 368, 772-773.	34.6	5
329	Atrial fibrillation is associated with increased mortality: causation or association?. <i>European Heart Journal</i> , 2013, 34, 1027-1030.	2.2	41
330	Effect of B Vitamins and Lowering Homocysteine on Cognitive Impairment in Patients With Previous Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2013, 44, 2232-2239.	6.0	80
331	The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. <i>European Heart Journal</i> , 2013, 34, 2752-2759.	2.2	22
332	Stroke prevention in older adults with atrial fibrillation. <i>Cmaj</i> , 2013, 185, 1479-1480.	1.2	6
333	Response to Letters Regarding Article, "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial". <i>Circulation</i> , 2013, 127, .	18.1	2
334	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 2192-2201.	18.1	298
335	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <i>European Heart Journal</i> , 2013, 34, 1498-1505.	2.2	114
336	Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 778-782.	3.8	10
337	A guide to GRADE guidelines for the readers of JTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1603-1608.	3.8	40
338	Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial. <i>Transfusion</i> , 2013, 53, 1487-1492.	0.8	13
339	A response to "There's madness in their methods." <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 785-786.	3.8	0
340	Association of atrial fibrillation with mortality and disability after ischemic stroke. <i>Neurology</i> , 2013, 81, 825-832.	1.0	131
341	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 37, 435-442.	1.9	11
342	Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 37, 362-371.	1.9	16

#	ARTICLE	IF	CITATIONS
343	Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality. <i>Blood</i> , 2013, 122, 3651-3651.	4.2	6
344	Preventing Thromboembolic Complications in Older Orthopaedic Surgery Patients. <i>Drugs and Aging</i> , 2012, 15, 297-306.	3.2	1
345	Homocysteine Levels in Patients with Stroke. <i>CNS Drugs</i> , 2012, 15, 437-443.	6.3	12
346	Failure of Aspirin to Prevent Atherothrombosis. <i>American Journal of Cardiovascular Drugs</i> , 2012, 4, 57-67.	2.4	9
347	Adjunctive Use of Direct Thrombin Inhibitors in Patients Receiving Fibrinolytic Therapy for Acute Myocardial Infarction. <i>American Journal of Cardiovascular Drugs</i> , 2012, 4, 107-115.	2.4	5
348	Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. <i>Circulation</i> , 2012, 126, 2309-2316.	18.1	141
349	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. <i>Circulation</i> , 2012, 125, 669-676.	18.1	348
350	The aspirin controversy in primary prevention. <i>Current Opinion in Cardiology</i> , 2012, 27, 499-507.	1.6	25
351	Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2012, 27, 331-339.	1.6	9
352	Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 250-256.	3.8	25
353	More on Acutely Injured Patients Receiving Dabigatran. <i>New England Journal of Medicine</i> , 2012, 366, 863-864.	34.6	5
354	Anticoagulants in Patients with Atrial Fibrillation and End-Stage Renal Disease. <i>Postgraduate Medicine</i> , 2012, 124, 17-25.	2.6	10
355	Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran. <i>Circulation</i> , 2012, 126, 2428-2432.	18.1	105
356	Sex, Stroke, and Atrial Fibrillation. <i>Archives of Neurology</i> , 2012, 69, 1641.	6.8	14
357	Treatment With B Vitamins and Incidence of Cancer in Patients With Previous Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2012, 43, 1572-1577.	6.0	21
358	Letter by Van de Werf et al Regarding Article, "Using Dabigatran in Patients With Stroke: A Practical Guide for Clinicians" • <i>Stroke</i> , 2012, 43, .	6.0	0
359	B Vitamins and Magnetic Resonance Imagingâ€œDetected Ischemic Brain Lesions in Patients With Recent Transient Ischemic Attack or Stroke. <i>Stroke</i> , 2012, 43, 3266-3270.	6.0	78
360	The hazards of interrupting anticoagulation therapy in atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 1864-1866.	2.2	12

#	ARTICLE	IF	CITATIONS
361	Which Risk Factors Are More Associated With Ischemic Stroke Than Intracerebral Hemorrhage in Patients With Atrial Fibrillation?. <i>Stroke</i> , 2012, 43, 2048-2054.	6.0	37
362	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , 2012, 33, 2143-2150.	2.2	90
363	Translational Success Stories. <i>Circulation Research</i> , 2012, 111, 920-929.	13.2	72
364	Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. <i>Lancet Neurology</i> , 2012, 11, 1066-1081.	17.9	78
365	Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 429-436.	1.9	13
366	Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 429-435.	1.6	101
367	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, 944-950.e3.	2.6	17
368	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , 2012, 129, 715-719.	2.3	39
369	Aspirin response variability after major orthopedic surgery. <i>Thrombosis Research</i> , 2012, 130, 216-220.	2.3	13
370	Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. <i>Stroke</i> , 2012, 43, 3291-3297.	6.0	92
371	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oral dabiGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN). <i>American Heart Journal</i> , 2012, 163, 931-937.e1.	2.9	168
372	Dabigatran for patients with a mechanical valve. <i>Heart Lung and Circulation</i> , 2012, 21, 121.	0.9	0
373	Anticoagulants in atrial fibrillation patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012, 8, 569-578.	32.8	72
374	Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2012, 367, 1979-1987.	34.6	522
375	The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2012, 107, 998-1000.	4.1	7
376	Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. <i>Thrombosis and Haemostasis</i> , 2012, 107, 8-14.	4.1	14
377	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1228-1235.	4.1	25
378	Direct thrombin inhibitors in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2012, 9, 402-414.	35.7	34

#	ARTICLE	IF	CITATIONS
379	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. <i>Circulation</i> , 2012, 126, 343-348.	18.1	529
380	Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. <i>Journal of Internal Medicine</i> , 2012, 271, 15-24.	7.3	48
381	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. <i>Lancet Neurology</i> , The, 2012, 11, 225-231.	17.9	176
382	Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 512-520.	17.9	75
383	The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. <i>Transfusion</i> , 2012, 52, 1203-1212.	0.8	63
384	The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. <i>Transfusion</i> , 2012, 52, 1363-1378.	0.8	12
385	Old blood bad? Either the biggest issue in transfusion medicine or a nonevent. <i>Transfusion</i> , 2012, 52, 1165-1167.	0.8	3
386	Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 229-235.	3.8	27
387	Reversal of the antiplatelet effects of aspirin and clopidogrel. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 521-528.	3.8	138
388	Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 966-968.	3.8	9
389	The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?. <i>International Journal of Stroke</i> , 2012, 7, 139-141.	6.4	7
390	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. <i>American Journal of Hematology</i> , 2012, 87, .	6.5	5
391	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 35, 295-301.	1.9	60
392	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. <i>Blood</i> , 2012, 120, 19-19.	4.2	7
393	Dabigatran Etxilate. <i>Circulation</i> , 2011, 123, 1436-1450.	18.1	348
394	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 806-817.	34.6	2,352
395	Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. <i>Thrombosis and Haemostasis</i> , 2011, 106, 571-584.	4.1	188
396	Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2011, 124, 621-629.	2.0	145

#	ARTICLE	IF	CITATIONS
397	Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. <i>Canadian Journal of Cardiology</i> , 2011, 27, 711-715.	2.6	11
398	Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism. <i>Annual Review of Medicine</i> , 2011, 62, 41-57.	18.7	183
399	Apixaban in Acute Coronary Syndromes. <i>Cardiovascular Therapeutics</i> , 2011, 29, 285-290.	5.4	5
400	Should adult patients be routinely tested for heritable thrombophilia after an episode of venous thromboembolism?. <i>Medical Journal of Australia</i> , 2011, 195, 139-142.	1.7	7
401	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial. <i>Annals of Internal Medicine</i> , 2011, 155, 660-667.	9.7	183
402	Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. <i>Annals of Internal Medicine</i> , 2011, 155, 579-586.	9.7	128
403	Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin release assay: a 30-month, 16-patient case series. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2389-2396.	3.8	128
404	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 378-385.	1.9	15
405	Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. <i>American Journal of Hematology</i> , 2011, 86, 603-606.	6.5	11
406	Effectiveness and safety of combined antiplatelet and anticoagulant therapy: A critical review of the evidence from randomized controlled trials. <i>Blood Reviews</i> , 2011, 25, 123-129.	5.1	43
407	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. <i>BMJ: British Medical Journal</i> , 2011, 342, c7270-c7270.	0.1	13
408	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	18.1	4,120
409	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 522-534.	4.8	104
410	New oral anticoagulants for stroke prevention in atrial fibrillation. <i>Clinical Investigation</i> , 2011, 1, 3-7.	0.3	3
411	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. <i>European Heart Journal</i> , 2011, 32, 2256-2265.	2.2	42
412	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	2.2	362
413	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	18.1	1,081
414	Current Evidence for Genetic Testing in Clopidogrel-Treated Patients Undergoing Coronary Stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 505-513.	4.8	18

#	ARTICLE	IF	CITATIONS
415	CYP2C19 Genetic Testing Should Not Be Done in All Patients Treated With Clopidogrel Who Are Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 514-521.	4.8	19
416	Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran. <i>Current Neurology and Neuroscience Reports</i> , 2011, 12, 17-23.	4.4	8
417	Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 33, 88-94.	1.9	117
418	New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. <i>Advances in Therapy</i> , 2010, 26, 1058-1071.	3.3	8
419	Point-of-care Testing for Assessment of Adequacy of Oral Antiplatelet Therapy in Patients With Cardiovascular Disease. <i>Future Cardiology</i> , 2010, 6, 289-299.	1.0	9
420	Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 127-132.	1.9	24
421	Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 434-440.	1.9	32
422	Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. <i>Lancet Neurology</i> , The, 2010, 9, 273-284.	17.9	84
423	Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 101-106.	3.8	82
424	Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the organization to assess strategies in acute ischemic syndromes (OASIS)-5 trial. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 243-249.	3.8	40
425	How can we reduce disagreement among guidelines for venous thromboembolism prevention?. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 675-677.	3.8	4
426	Does dabigatran improve stroke prevention in atrial fibrillation? Reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1438-1439.	3.8	3
427	A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1966-1975.	3.8	75
428	The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe?. <i>Thrombosis and Haemostasis</i> , 2010, 104, 45-48.	4.1	126
429	Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 382-387.	6.0	37
430	Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. <i>Circulation</i> , 2010, 121, 1188-1199.	18.1	436
431	Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Stents. <i>Circulation</i> , 2010, 121, 2067-2070.	18.1	113
432	New Anticoagulants. <i>Circulation</i> , 2010, 121, 1523-1532.	18.1	266

#	ARTICLE	IF	CITATIONS
433	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. <i>European Heart Journal</i> , 2010, 31, 50-58.	2.2	93
434	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2010, 363, 930-942.	34.6	719
435	Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment. <i>New England Journal of Medicine</i> , 2010, 363, 1704-1714.	34.6	521
436	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. <i>Thrombosis Research</i> , 2010, 125, e128-e131.	2.3	11
437	Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. <i>American Heart Journal</i> , 2010, 159, 348-353.e1.	2.9	153
438	Duration of red cell storage before transfusion and in-hospital mortality. <i>American Heart Journal</i> , 2010, 159, 737-743.e1.	2.9	103
439	Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. <i>American Heart Journal</i> , 2010, 160, 1178-1184.	2.9	94
440	Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. <i>American Heart Journal</i> , 2010, 160, 1049-1055.	2.9	16
441	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010, 376, 1233-1243.	62.3	748
442	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet, The</i> , 2010, 376, 975-983.	62.3	937
443	New antithrombotic agents—insights from clinical trials. <i>Nature Reviews Cardiology</i> , 2010, 7, 498-509.	35.7	48
444	Dabigatran: ready for prime time?. <i>Polish Archives of Internal Medicine</i> , 2010, 120, 137-142.	0.6	2
445	Low-Molecular-Weight Heparin as an Adjunct to Thrombolysis in ST Elevation Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2009, 169, 1163.	8.1	6
446	Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials. <i>Circulation</i> , 2009, 120, 2006-2011.	18.1	79
447	Accelerated Infusion of Streptokinase for the Treatment of Left-Sided Prosthetic Valve Thrombosis. <i>Circulation</i> , 2009, 120, 1108-1114.	18.1	71
448	Response to Letter Regarding Article, "Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk". <i>Circulation</i> , 2009, 119, .	18.1	3
449	New Anticoagulants for Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 515-524.	2.5	51
450	Ethnicity Does Not Affect the Homocysteine-Lowering Effect of B-Vitamin Therapy in Singaporean Stroke Patients. <i>Stroke</i> , 2009, 40, 2209-2211.	6.0	7

#	ARTICLE	IF	CITATIONS
451	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009, 84, 579-583.	6.5	28
452	Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. <i>British Journal of Haematology</i> , 2009, 146, 142-149.	2.7	42
453	Postoperative Low-Molecular-Weight Heparin Bridging Is Associated with an Increase in Wound Hematoma Following Surgery for Pacemakers and Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 378-382.	1.1	94
454	Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: A systematic review of randomized trials. <i>Thrombosis Research</i> , 2009, 123, 687-696.	2.3	320
455	Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. <i>American Heart Journal</i> , 2009, 157, 60.e1-60.e9.	2.9	17
456	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. <i>American Heart Journal</i> , 2009, 158, 881-886.e1.	2.9	32
457	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	34.6	10,494
458	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. <i>Canadian Journal of Cardiology</i> , 2009, 25, 683-689.	2.6	78
459	Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. <i>Lancet</i> , The, 2009, 374, 565-576.	62.3	213
460	Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding. <i>Annals of Internal Medicine</i> , 2009, 150, 379-386.	9.7	157
461	Deep Vein Thrombosis Prophylaxis: Response. <i>Chest</i> , 2009, 136, 1700-1701.	1.0	3
462	New oral anticoagulants: not quite there yet. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 53-59.	0.6	9
463	Clinical factors influencing the sensitivity to warfarin when restarted after surgery. <i>Journal of Internal Medicine</i> , 2008, 263, 412-419.	7.3	14
464	The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2008, 8, .	2.0	55
465	What do the results of the PROFESS trial teach us?. <i>Lancet Neurology</i> , The, 2008, 7, 860-862.	17.9	8
466	Gastrointestinal bleeding after acute ischemic stroke. <i>Neurology</i> , 2008, 71, 650-655.	1.0	81
467	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 766-780.	0.0	82
468	Homocysteine or Renal Impairment. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1158-1164.	6.0	64

#	ARTICLE	IF	CITATIONS
469	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. <i>Circulation</i> , 2008, 118, 2029-2037.	18.1	821
470	Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke. <i>Stroke</i> , 2008, 39, 1638-1646.	6.0	47
471	The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. <i>European Heart Journal</i> , 2008, 29, 1057-1071.	2.2	142
472	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2008, 30, 655-661.	2.2	157
473	Response to Letter Regarding Article, "Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation". <i>Circulation</i> , 2008, 117, .	18.1	0
474	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2008, 118, 2038-2046.	18.1	100
475	Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid. <i>Circulation</i> , 2008, 118, 1705-1712.	18.1	221
476	Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. <i>Country Review Ukraine</i> , 2008, 10, C8-C13.	1.3	12
477	The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. <i>Current Opinion in Cardiology</i> , 2008, 23, 327-334.	1.6	16
478	Management of peripheral arterial disease in the elderly: focus on cilostazol. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 17-23.	6.1	11
479	The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. <i>Medical Journal of Australia</i> , 2008, 189, 144-147.	1.7	85
480	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2007, 28, 1193-1204.	2.2	259
481	Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. <i>Circulation</i> , 2007, 116, 449-455.	18.1	82
482	Inherited thrombophilia and pregnancy associated venous thromboembolism. <i>BMJ: British Medical Journal</i> , 2007, 334, 1318-1321.	0.1	43
483	Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. <i>New England Journal of Medicine</i> , 2007, 357, 217-227.	34.6	417
484	Treatment of Restenosis with a Paclitaxel-Coated Balloon Catheter. <i>New England Journal of Medicine</i> , 2007, 356, 1071-1073.	34.6	4
485	Platelet Function Testing: Quality Assurance. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 273-282.	2.5	65
486	Latest medical treatment strategies for venous thromboembolism. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1221-1233.	2.1	11

#	ARTICLE	IF	CITATIONS
487	Beyond Unfractionated Heparin and Warfarin. <i>Circulation</i> , 2007, 116, 552-560.	18.1	209
488	Aspirin resistance. <i>Thrombosis Research</i> , 2007, 120, 337-346.	2.3	52
489	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1742-1751.	2.3	261
490	Guidelines for the management of acute coronary syndromes 2006. <i>Medical Journal of Australia</i> , 2007, 186, 101-102.	1.7	0
491	Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 255-263.	3.8	86
492	Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1438-1443.	3.8	111
493	Bleeding Complications in Acute Coronary Syndromes and Percutaneous Coronary Intervention: Predictors, Prognostic Significance, and Paradigms for Reducing Risk. <i>Clinical Cardiology</i> , 2007, 30, 1124-1134.	2.0	45
494	Role of protein Z in stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 9, 191-197.	0.5	2
495	Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency. <i>Annals of Internal Medicine</i> , 2006, 144, 673-684.	9.7	392
496	Aspirin resistance. <i>Lancet</i> , The, 2006, 367, 606-617.	62.3	546
497	Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2006, 114, 774-782.	18.1	1,244
498	Monitoring unfractionated heparin with the aPTT: Time for a fresh look. <i>Thrombosis and Haemostasis</i> , 2006, 96, 547-552.	4.1	150
499	Homocysteine-Should We Screen and Treat in Preventive Cardiology Programs?. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2006, 26, 281-287.	0.7	0
500	The tissue factor pathway in ischemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 527-532.	1.0	15
501	More on: enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1639-1640.	3.8	1
502	Bleeding and management of bleeding. <i>Country Review Ukraine</i> , 2006, 8, G38-G45.	1.3	64
503	Methylenetetrahydrofolate Reductase Polymorphisms and Homocysteine-Lowering Effect of Vitamin Therapy in Singaporean Stroke Patients. <i>Stroke</i> , 2006, 37, 456-460.	6.0	38
504	Management of Antiphospholipid Antibody Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1050.	16.6	401

#	ARTICLE	IF	CITATIONS
505	Medical Treatment of Peripheral Arterial Disease. JAMA - Journal of the American Medical Association, 2006, 295, 547.	16.6	295
506	Risk of Recurrent Venous Thromboembolism in Patients With Common Thrombophilia. Archives of Internal Medicine, 2006, 166, 729.	8.1	273
507	The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin. Evidence-Based Medicine, 2006, 11, 120-120.	0.8	1
508	Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). Vascular Health and Risk Management, 2006, 2, 379-387.	4.1	4
509	High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis. Journal of Thrombosis and Haemostasis, 2005, 3, 1094-1095.	3.8	21
510	Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Journal of Thrombosis and Haemostasis, 2005, 3, 1309-1311.	3.8	321
511	Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. Journal of Thrombosis and Haemostasis, 2005, 3, 2649-2655.	3.8	50
512	Bone marrow biopsy in thrombocytopenic or anticoagulated patients. British Journal of Haematology, 2005, 129, 562-563.	2.7	13
513	Bone marrow biopsy morbidity and mortality: 2002 data.. International Journal of Laboratory Hematology, 2005, 27, 209-210.	0.1	1
514	von Willebrand Disease Associated with Superficial Temporal Artery Pseudoaneurysm. European Journal of Vascular and Endovascular Surgery, 2005, 30, 285-287.	2.0	7
515	Venous thromboembolism: diagnosis and management of deep venous thrombosis. Medical Journal of Australia, 2005, 182, 476-481.	1.7	39
516	Venous thromboembolism: diagnosis and management of pulmonary embolism. Medical Journal of Australia, 2005, 183, 220-221.	1.7	0
517	Venous thromboembolism: diagnosis and management of pulmonary embolism. Medical Journal of Australia, 2005, 182, 569-574.	1.7	25
518	Adding aspirin to clopidogrel after TIA and ischemic stroke. Neurology, 2005, 64, 1117-1121.	1.0	21
519	Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction. Circulation, 2005, 112, 3855-3867.	18.1	137
520	Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. Canadian Journal of Physiology and Pharmacology, 2005, 83, 98-103.	1.8	15
521	Homocysteine-Lowering Treatment With Folic Acid, Cobalamin, and Pyridoxine Does Not Reduce Blood Markers of Inflammation, Endothelial Dysfunction, or Hypercoagulability in Patients With Previous Transient Ischemic Attack or Stroke. Stroke, 2005, 36, 144-146.	6.0	97
522	Protein Z Gene Polymorphisms, Protein Z Concentrations, and Ischemic Stroke. Stroke, 2005, 36, 1123-1127.	6.0	53

#	ARTICLE	IF	CITATIONS
523	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2005, 26, 2396-2403.	2.2	24
524	Clinical usefulness of plasma homocysteine in vascular disease. <i>Medical Journal of Australia</i> , 2004, 181, 314-318.	1.7	47
525	Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. <i>Medical Journal of Australia</i> , 2004, 181, 150-154.	1.7	90
526	Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 493-503.	2.1	18
527	Red cell N5-methyltetrahydrofolate concentrations and C677T methylenetetrahydrofolate reductase genotype in patients with stroke. <i>Journal of Clinical Pathology</i> , 2004, 57, 54-57.	1.7	10
528	Ximelagatran or Warfarin for Stroke Prevention in Patients With Atrial Fibrillation?. <i>Stroke</i> , 2004, 35, 389-391.	6.0	17
529	Folic Acid-Based Multivitamin Therapy to Prevent Stroke. <i>Stroke</i> , 2004, 35, 1995-1998.	6.0	9
530	Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2067-2069.	3.8	37
531	Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism. <i>Circulation</i> , 2004, 110, 744-749.	18.1	608
532	Renal Function, Peak Anti-Xa Levels and Enoxaparin Dosing. <i>Journal of Pharmacy Practice and Research</i> , 2004, 34, 14-17.	0.8	8
533	Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 129-130.	1.0	2
534	Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2004, 140, 175-183.	9.7	342
535	Low-Molecular-Weight Heparin for Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2004, 141, 407-408.	9.7	0
536	Collagen platelet receptor polymorphisms integrin $\alpha 2\beta 1$ C807T and GPVI Q317L and risk of ischemic stroke. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 963-970.	3.8	35
537	SUBOPTIMAL PREVENTIVE PRACTICES IN PATIENTS WITH CAROTID AND PERIPHERAL VASCULAR OCCLUSIVE DISEASE IN A TERTIARY REFERRAL SETTING. <i>ANZ Journal of Surgery</i> , 2003, 73, 932-937.	1.2	12
538	Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia. <i>ANZ Journal of Surgery</i> , 2003, 73, 826-829.	1.2	9
539	Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2689-2691.	3.8	44
540	The evolving role of direct thrombin inhibitors in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 41, S70-S78.	2.3	35

#	ARTICLE	IF	CITATIONS
541	C-reactive protein in ischemic stroke and its etiologic subtypes. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2003, 12, 74-81.	1.6	42
542	Does This Patient Have Pulmonary Embolism?. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 2849.	16.6	155
543	Editorial Commentâ€”Routine Thrombophilia Testing in Stroke Patients Is Unjustified. <i>Stroke</i> , 2003, 34, 1826-1827.	6.0	15
544	Endothelial and Platelet Activation in Acute Ischemic Stroke and Its Etiological Subtypes. <i>Stroke</i> , 2003, 34, 2132-2137.	6.0	158
545	Protein Z in Ischemic Stroke and its Etiologic Subtypes. <i>Stroke</i> , 2003, 34, 2415-2419.	6.0	76
546	Antiplatelet Agents in Acute Coronary Syndromes. <i>Seminars in Vascular Medicine</i> , 2003, 03, 403-414.	3.2	4
547	Recombinant activated factor VII for the treatment of life-threatening haemorrhage. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 713-717.	1.0	81
548	Venous thromboembolism in travellers. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 671-675.	1.0	21
549	Antiplatelet drugs. <i>Medical Journal of Australia</i> , 2003, 178, 568-574.	1.7	57
550	Review: MTHFR TT genotype increases risk for coronary heart disease. <i>ACP Journal Club</i> , 2003, 138, 79.	0.1	0
551	Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. <i>Circulation</i> , 2002, 105, 1650-1655.	18.1	1,063
552	Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2002, 23, 117-123.	2.2	26
553	Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2002, 23, 1771-1779.	2.2	60
554	Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement. <i>Archives of Internal Medicine</i> , 2002, 162, 1465.	8.1	174
555	Low molecular weight heparins and heparinoids. <i>Medical Journal of Australia</i> , 2002, 177, 379-383.	1.7	42
556	Recurrent palmar-plantar erythrodysesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2002, 69, 315-317.	1.8	12
557	Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction11 Drs. Mehta and Eikelboom were recipients of Heart and Stroke Foundation of Canada Research Fellowship Awards. Professor Yusuf is the recipient of a Medical Research Council of Canada Senior Scientist Award and holds a Heart and Stroke Foundation of Ontario Research Chair. <i>Journal of the American College of Cardiology</i> , 2001, 37, 37-43.	2.3	392
558	Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. <i>Lancet</i> , The, 2001, 358, 9-15.	62.3	502

#	ARTICLE	IF	CITATIONS
559	Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 377-383.	2.2	18
560	Platelet glycoprotein Ib β Kozak polymorphism is associated with an increased risk of ischemic stroke. <i>Blood</i> , 2001, 98, 36-40.	4.2	94
561	Homocysteine and stroke. <i>Current Opinion in Neurology</i> , 2001, 14, 95-102.	3.7	114
562	Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 444.	16.6	30
563	Detection of protein s deficiency: a new functional assay compared to an antigenic technique. <i>Pathology</i> , 2000, 32, 94-97.	1.6	5
564	Association Between High Homocyst(e)ine and Ischemic Stroke due to Large- and Small-Artery Disease but Not Other Etiologic Subtypes of Ischemic Stroke. <i>Stroke</i> , 2000, 31, 1069-1075.	6.0	234
565	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. <i>Lancet, The</i> , 2000, 355, 1936-1942.	62.3	440
566	Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. <i>Lancet, The</i> , 2000, 356, 449-454.	62.3	76
567	Homocyst(e)ine and Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2000, 132, 676.	9.7	10
568	Prothrombin 20210A and familial thrombophilia. <i>Blood Coagulation and Fibrinolysis</i> , 1999, 10, 523-527.	1.0	0
569	Homocysteine and vascular disease. <i>Lancet, The</i> , 1999, 354, 407-413.	62.3	948
570	Broadsheet number 53: activated protein c resistance: diagnosis and clinical management. <i>Pathology</i> , 1999, 31, 365-371.	1.6	0
571	Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence. <i>Annals of Internal Medicine</i> , 1999, 131, 363-375.	9.7	801
572	Venous thrombosis and hyperhomocysteinaemia. <i>Medical Journal of Australia</i> , 1998, 169, 313-315.	1.7	4
573	Exacerbation of coagulopathy with concurrent bone marrow necrosis, hepatic and renal dysfunction secondary to all-trans retinoic acid therapy for acute promyelocytic leukemia. , 1997, 15, 13-17.		4
574	Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 0, , 15476.	0.1	84
575	Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy. <i>The Cochrane Library</i> , 0, , .	2.2	3
576	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. <i>European Cardiology Review</i> , 0, 16, .	2.3	10

#	ARTICLE	IF	CITATIONS
577	Adult malaria mortality during 2019 at Bo Government Hospital, Sierra Leone. <i>Gates Open Research</i> , 0, 7, 48.	0.7	2
578	Risk factors associated with gastrointestinal bleeding in patients with cardiovascular disease (INTERBLEED): a case control study. <i>European Journal of Preventive Cardiology</i> , 0, , .	2.0	2
579	Atrial fibrillation and atherosclerosis cause different vascular brain lesions on magnetic resonance imaging. <i>European Heart Journal</i> , 0, 46, 5177-5188.	2.2	2
580	Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 0, 9, 103191.	0.5	0
581	Routine left atrial appendage closure in non-AF patients: an unresolved issue. <i>European Heart Journal</i> , 0, , .	2.2	0
582	Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 0, , .	4.0	0